Trial Profile
Trastuzumab emtansine (Kadcyla) in patients with HER2-positive inoperable or recurrent breast cancer in Japan
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 02 Dec 2013
Price :
$35
*
At a glance
- Drugs Trastuzumab emtansine (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- Sponsors Chugai Pharmaceutical
- 02 Dec 2013 This trial is planned to continue until the price of Kadcyla is listed in Japan and the product is launched there, according to a Chugai Pharmaceutical media release.
- 02 Dec 2013 New trial record